Literature DB >> 35300879

Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer.

Rosalind P Candelaria1, Beatriz E Adrada2, Deanna L Lane2, Gaiane M Rauch2, Stacy L Moulder3, Alastair M Thompson4, Roland L Bassett5, Elsa M Arribas2, Huong T Le-Petross2, Jessica W T Leung2, David A Spak2, Elizabeth E Ravenberg3, Jason B White3, Vicente Valero3, Wei T Yang2.   

Abstract

This study aimed to investigate mid-treatment breast tumor ultrasound characteristics that may predict eventual pathologic complete response (pCR) in triple-negative breast cancer; specifically, we examined associations between pCR and two parameters: tumor response pattern and tumor appearance. Ultrasound was performed at mid-treatment, defined as the completion of four cycles of anthracycline-based chemotherapy and before receiving taxane-based chemotherapy. Consensus imaging review was performed while blinded to pathology results (i.e., pCR/non-pCR) from surgery. Tumor response pattern was described as "complete," "concentric," "fragmented," "stable" or "progression." Tumor appearance was designated as "mass," "architectural distortion," "flat tumor bed" or "clip only." Univariate and multivariate regression analyses of 144 participants showed significant associations between mid-treatment response pattern and pCR (p = 0.0348 and p = 0.0173, respectively), with complete and concentric response patterns more likely to achieve pCR than other patterns. Univariate and multivariate regression analyses further showed significant associations between mid-treatment tumor appearance and pCR (p < 0.0001 for both), with persistent appearance of mass less likely than other appearances to achieve pCR. To conclude, our study demonstrated strong associations between pCR and both tumor response pattern and tumor appearance, thereby suggesting that these parameters have potential as qualitative imaging biomarkers of pCR in triple-negative breast cancer.
Copyright © 2022 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neoadjuvant therapy; Treatment response; Triple-negative breast cancer; Ultrasound

Mesh:

Substances:

Year:  2022        PMID: 35300879      PMCID: PMC9050953          DOI: 10.1016/j.ultrasmedbio.2022.01.018

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  28 in total

1.  Triple-negative breast cancer: clinical features and patterns of recurrence.

Authors:  Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.

Authors:  Jason D Keune; Donna B Jeffe; Mario Schootman; Abigail Hoffman; William E Gillanders; Rebecca L Aft
Journal:  Am J Surg       Date:  2010-04       Impact factor: 2.565

3.  Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.

Authors:  Rosalind P Candelaria; Roland L Bassett; William Fraser Symmans; Maheshwari Ramineni; Stacy L Moulder; Henry M Kuerer; Alastair M Thompson; Wei Tse Yang
Journal:  Oncologist       Date:  2017-03-17

4.  Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy.

Authors:  Laura Ballesio; Silvia Gigli; Francesca Di Pastena; Guglielmo Giraldi; Lucia Manganaro; Emanuela Anastasi; Carlo Catalano
Journal:  Tumour Biol       Date:  2017-03

5.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

6.  Pathologic changes related to CMF primary chemotherapy in breast cancer. Pathological evaluation of response predicts clinical outcome.

Authors:  Abelardo Moreno; Agustín Escobedo; Enrique Benito; Jose Ma Serra; Anna Gumà; Francisco Riu
Journal:  Breast Cancer Res Treat       Date:  2002-09       Impact factor: 4.872

7.  Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer.

Authors:  Christos Hatzis; W Fraser Symmans; Ya Zhang; Rebekah E Gould; Stacy L Moulder; Kelly K Hunt; Maysa Abu-Khalaf; Erin W Hofstatter; Donald Lannin; Anees B Chagpar; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2015-08-18       Impact factor: 12.531

8.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

9.  Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).

Authors:  M E M van der Noordaa; F H van Duijnhoven; C E Loo; E van Werkhoven; K K van de Vijver; T Wiersma; H A O Winter-Warnars; G S Sonke; M T F D Vrancken Peeters
Journal:  Breast       Date:  2018-05-22       Impact factor: 4.380

10.  Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.

Authors:  I Gounaris; E Provenzano; A L Vallier; L Hiller; M Iddawela; S Hilborne; K Taylor; P Britton; H M Earl; R Sinnatamby
Journal:  Breast Cancer Res Treat       Date:  2011-03-25       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.